|
CIDPUSA and Nanotech Medical centers combined to
do a 20 year research study and published the
autoimmune diseases E-BOOK which contains treatment of alzheimers,
CIDP, neuropathies, Pemphigus, acne, alopecia , every type of
arthritis and many more by simple antibiotics. Save your money and
purchase this book online today 24 hour delivery to your email.
Check this offer on our home page.
Read this
link too!
Peripheral Neuropathy
guidelines
most of neuropathy is really
CIDP.
Part-1 Part-2
 |
| |
|
Table 10. Tests
to Consider for Patients with Suspected
Peripheral Neuropathy
|
|
Test |
Indications |
Interpretation |
|
Laboratory |
|
CBC, erythrocyte sedimentation rate |
Conduct in most patients |
Commonly abnormal in systemic disease.
Erythroblastic anemia suggests vitamin B12
or folate deficiency; erythrocyte stippling
suggests lead toxicity. |
|
Blood sugar, hemoglobin A1C |
Suspected diabetic PN
Undiagnosed PN |
Symptoms of neuropathy may be the first
presentation of diabetes mellitus |
|
Blood chemistry battery (e.g., SMA 20) |
Conduct in most patients |
Detects renal insufficiency and other
metabolic disorders |
|
Vitamin B12
levels |
Conduct in most patients
Suspected nutritional PN |
CNS and posterior-column manifestations may
obscure PN; folate treatment normalizes CBC,
but does not prevent progressive neurologic
injury |
|
Serum protein electrophoresis |
Conduct in most patients |
If a paraprotein is identified, request a
bone survey and consider bone biopsy to rule
out multiple myeloma or osteosclerotic
myeloma. |
|
Serum creatinine kinase (CK) |
Suspected motor-neuron disease (MND) |
Moderate CK elevation is often supportive of
MND diagnosis [6] |
|
Serologic testing for syphilis, HIV, Lyme
disease; tuberculin skin test; antinuclear
antibodies; urine tests for aminolevulinic
acid, porphobilinogen; urine
immunoelectrophoresis; 24-hr urine test for
heavy metals (Pb, TI, As) |
In selected patients with suggestive
clinical indications |
Yield is very low in the absence of specific
clinical indications |
|
Cerebral spinal fluid examination |
May be particularly helpful in patients with
predominant sensory neuropathy, with or
without corticospinal findings, and in
paraneoplastic neuropathies [5] |
CSF protein will be elevated in >90% of
patients with acute and chronic inflammatory
demyelinating polyneuropathy; it is also
frequently elevated in paraneoplastic
sensory neuropathy [21]. Elevated total
protein with <5 cells/mm3 suggest
Gullain-Barré syndrome or chronic
inflammatory demyelinating
polyradiculoneuropathy (CIDP). |
|
Radiologic |
|
MRI |
Suspected nerve compression (e.g., carpal
tunnel syndrome) |
Used primarily to confirm peripheral-nerve
entrapments/compressions or root disease |
|
Invasive |
|
Nerve biopsy |
Considered when there is a specific
diagnosis in mind or when no etiology is
evident from serologic and electrodiagnostic
tests |
Diagnostic abnormalities present in [2]:
Vasculitis
Amyloidosis
Sarcoidosis
Leprosy
Hereditary neuropathy with liability to
pressure palsies
Giant axonal neuropathy
Metachromatic leukodystrophy
Paraproteinemic neuropathy
Tumor infiltration |
|
Based on Bosch [2], Logigian [5], Barohn
[6]. |
|
Table 11.
Electrodiagnostic Studies: Key Measurements
|
|
Study |
Key measurement |
Nerves measured |
Important parameters |
|
Motor conduction |
Compound muscle action potential (CMAP) |
Ulnar
Median
Peroneal
Posterior tibial |
Latency
Amplitude
Conduction velocity
F wave
H reflex |
|
Sensory conduction |
Sensory-nerve action potential (SNAP) |
Ulnar
Median
Radial
Sural |
Latency
Amplitude
|
|
Needle electromyography |
Configuration and size of individual motor
unit potentials |
Not relevant |
Spontaneous activity
Firing pattern |
|
Table 12.
Electrodiagnostic Studies: Terminology
|
|
Parameter |
Definition |
|
Amplitude |
In motor-conduction studies: height in
millivolts of CMAP from baseline to peak,
i.e., number of muscle fibers activated by
stimulus at a particular site
In sensory-conduction studies: height
in microvolts of SNAP from baseline to peak |
|
CMAP |
Summation of all muscle-fiber action
potentials activated by motor nerve
stimulation |
|
Conduction velocity |
Speed in meters per second of nerve impulse
conduction |
|
F wave |
Assesses conduction along the proximal
portion of the motor nerve; most commonly
used in evaluating demyelinating
neuropathies |
|
Firing pattern |
The number, size, and shape of motor units
that initially fire and then recruit other
motor units to fire, following voluntary
muscle contraction |
|
H reflex |
Analogous to the ankle-jerk reflex but
reflex is stimulated by a submaximal
electrical current that selectively
activates IA afferent sensory fibers (to
cause a motor reflex) |
|
Latency |
In motor-conduction studies: time in
milliseconds for conduction of a stimulus
along the length of the nerve, transmission
of the neurotransmitter-mediated signal
across the neuromuscular junction, and
depolarization of the muscle-fiber membrane
In sensory-conduction studies:
conduction time of the fastest-conducting
fibers along a given segment |
|
SNAP |
Summation of individual action potentials of
all the fibers activated |
|
Spontaneous activity |
Measures endplate muscle activity when a
needle is placed near the neuromuscular
junction (including spontaneous discharges -
i.e., fibrillations and fasciculations - of
muscle activity at rest) |
|
CMAP, compound muscle action potential;
SNAP, sensory nerve action potential. |
|
Based on Raynor [3], Lynn and Mendell [11]. |
|
Table 13.
Electrophysiologic Findings of Axonal vs.
Demyelinating Peripheral Neuropathies
|
|
Study |
Axonal degeneration |
Segmental demyelination |
|
Motor-nerve conduction studies |
|
CMAPa
amplitude |
Decreased |
Normalb |
|
Distal latency |
Normal |
Prolonged |
|
Conduction velocity |
Normal |
Slow |
|
Conduction block |
Absent |
Present |
|
Temporal dispersion |
Absent |
Present |
|
F wave |
Normal |
Prolonged or absent |
|
H reflex |
Normal |
Prolonged or absent |
|
Sensory-nerve conduction studies |
SNAP amplitude
Distal latency
Conduction velocity |
Decreased
Normal
Normal |
Normal
Prolonged
Slow |
|
Needle electromyography (spontaneous
activity) |
|
Fibrillations |
Present |
Absent |
|
Fasciculations |
Present |
Absent |
|
Recruitment |
|
Number of motor units |
Decreased |
Decreased
|
a Compound motor action
potential.
b Except with conduction
block. |
|
Reprinted with permission from Barohn R:
Approach to peripheral neuropathy and
neuronopathy. Semin Neurol.
1998;18(1):7-18. |
|
Table 14.
Categorical Classification of Selected
Peripheral Neuropathies
|
|
Axonal |
Demyelinating |
|
Mononeuropathies |
|
Diabetes |
Entrapments |
|
Generalized neuropathies |
Diabetes
Alcohol
Carcinoma
Vitamin deficiencies
Toxic/metabolic neuropathies [Table 6],
including heavy metals, industrial solvents
and hydrocarbons, and medications
Hereditary peroneal muscular atrophy
Familial amyloidosis
Porphyria
Whipple s
disease
Leprosy |
Guillain-Barré syndrome
Leprosy
Hereditary peroneal muscular
atrophy/Dejerine-Sottas disease
Diphtheria
Chronic inflammatory demyelinating
polyneuropathy (CIDP)
Toxic neuropathies |
|
|
Table 3. Distribution
of Neuropathies by Age and in General
Population
|
|
Subcategorya |
Age <49 |
Age >50 |
Overall population |
|
Mononeuropathy |
|
|
35% |
50% |
30% |
|
Generalized neuropathies |
|
Toxic/metabolic |
60% |
55% |
69%a |
|
Hereditary |
5% |
<1% |
30%a |
|
Malignancy |
2% |
10% |
5% |
|
Idiopathic |
8% |
5% |
5% |
|
a Categories coexist in up
to one-third of cases. |
|
Table 4.
Age-Related Changes in the Peripheral
Nervous System
|
|
Type |
Changes |
|
Clinical |
Decreased vibratory sense
Decreased threshold response to tactile
stimuli, but normal threshold response to
pain
No change in position sense
Decreased muscle bulk and strength |
|
Histologic |
Reduction in number of nerve fibers
Preferential loss of large-diameter fibers
Reduction in muscle-fiber size
Decline in number of motor units (distal
muscles)
Evidence of denervation and reinnervation
with advancing age |
|
Physiologic |
Decline in motor- and sensory-nerve
conduction velocity (MCV)
Decreased amplitude in sensory-nerve action
potential (SNAP)
Increased amplitude and duration of
voluntary motor units suggesting denervation
and reinnervation |
|
Table 5. Signs
and Symptoms of Peripheral-Nerve Disorders
|
|
System |
Positive |
Negative |
|
Motora |
Cramps
Fasciculations
Myokymia (quivering)
Restless legs
Tightness |
Weakness
Fatigability
Hypotonia
Areflexia
Deformities (pes cavus, claw hand) |
|
Sensory (large fiber)b |
Paresthesias
Tingling |
Loss of vibration sense
Loss of joint position sense
Areflexia
Sensory ataxia (positive Romberg test)
Hypotonia |
|
Sensory (small fiber)c |
Burning, jabbing pain (dysesthesias) |
Loss of pain sense
Loss of temperature sense |
|
Autonomicd |
Hyperhidrosis
Excess saliva |
Orthostasis
Erectile dysfunction
Bowel and/or bladder dysfunction
Anhidrosis |
a All motor fibers are
large fibers.
b Mediate vibration,
proprioception, touch.
c Mediate pain,
temperature sensations.
d All autonomic fibers are
small fibers. |
|
Table 6. Drugs
and Toxins Causing Peripheral Neuropathy
|
|
Drug |
Special features |
|
Antibiotics |
|
Chloramphenicol |
Distal, primarily sensory neuropathy, optic
neuritis during prolonged high-dose use |
|
Dapsone |
Predominantly motor neuropathy |
Dideoxycytidine, dideoxyinosine,
Dideoxythmidine |
Painful sensory neuropathy |
|
Ethambutol |
Optic neuritis |
|
Isoniazid |
Distal axonal neuropathy, paresthesiae are
prominent. Prevented by vitamin B6 |
|
Metronidazole |
Distal sensory neuropathy |
|
Nitrofurantoin |
Distal sensorimotor neuropathy; occurs in
renal failure |
|
Suramin |
Distal sensorimotor and demyelinating
neuropathy |
|
Antineoplastics |
|
Cisplatin |
Sensory ataxia |
|
Cytarabine |
Sensorimotor neuropathy; rare |
|
Misonidazole |
Painful sensory neuropathy |
|
Procarbazine |
Distal paresthesias |
|
Paclitaxel |
Distal sensorimotor neuropathy |
|
Vinca alkaloids: vincristine, vinblastine,
vindesine, vinorelbine |
Distal sensorimotor neuropathy |
|
Antirheumatics |
|
Chloroquine |
Neuromyopathy |
|
Chlochicine |
Mild sensory neuropathy, myopathy |
|
Organic gold |
Demyelinating sensorimotor neuropathy |
|
Penicillamine |
Demyelinating sensorimotor neuropathy |
|
Other pharmaceuticals |
|
Amiodarone |
Mild sensorimotor neuropathy |
|
Disulfiram |
Distal sensorimotor neuropathy |
|
Ergots |
Distal paresthesiae and dysesthesiae |
|
FK 506 |
Axonal neuropathy |
|
Hydralazine |
Prevented by vitamin B6 |
|
Nitrous oxide |
Associated with myelopathy |
|
Perhexiline |
Demyelinating neuropathy |
|
Phenytoin |
Mild distal sensory loss |
|
Procainamide |
Demyelinating neuropathy; rare |
|
Pyridoxine |
Sensory ataxia |
|
Thalidomide |
Painful axonal neuropathy, primarily sensory |
|
L-Tryptophan |
Associated eosinophilia, fasciitis |
|
Nonpharmaceutical toxic agents |
|
Acrylamide |
Excessive sweating |
|
Allyl chloride |
Distal numbness |
|
Arsenic |
Elevated hair, urine, and fingernail levels |
|
Buckthorn |
Motor neuron syndrome causing bulbar and
limb paralysis |
|
Cadmium |
Sensory neuronopathy |
|
Propionitriles (e.g.,
dimethylaminopropionitrile) |
Urinary hesitancy, sexual dysfunction |
|
Ethylene oxide |
Associated cognitive impairment |
|
Hexacarbons (n-hexane, methyl n-butyl
ketone) |
Distal axonopathy |
|
Lead |
Predominantly motor; associated anemia |
|
Mercury |
Associated central nervous system
manifestations |
|
Methyl bromide |
Calf-muscle tenderness |
|
Organophosphorus esters |
Diarrhea, sweating, fasciculations |
|
Polychlorinated biphenyls |
Acne, brown-pigmented nails |
|
Thallium |
Gastrointestinal symptoms, delayed alopecia |
|
Trichlorethylene |
Facial numbness |
|
Vacor |
Acute diabetes mellitus |
|
Based on Lynn and Mendell [11]. |
|
Table 7. Key
Findings from History and Physical
Examination: Pattern Recognition for
Generalized Neuropathies
|
|
Pattern |
Classification/possible diagnoses |
Comments |
|
Symmetric proximal and distal weakness with
sensory loss |
Inflammatory demyelinating polyneuropathy
Guillain-Barré syndrome (GBS)
Chronic inflammatory demyelinating
polyneuropathy |
Patient complaints include: difficulty
raising arms to brush teeth and comb hair,
problems climbing stairs, difficulty rising
from a seated position, sensory loss, and
sensory ataxia |
|
Symmetric distal weakness with sensory loss |
Metabolic disorders (e.g., amyloidosis,
diabetes, Sjögrens syndrome)
Drugs (amitriptyline, chloroquine, dapsone)
and toxins
Hereditary neuropathies (Charcot-Marie-Tooth
disease, amyloidosis) |
Underlying conditions may be axonal or
demyelinating;
therefore, laboratory investigations (e.g.,
fasting blood sugar, hemoglobin
A1C, vitamin B12
levels, molecular genetic blood tests) are
recommended based on initial suspicions |
|
Asymmetric distal weakness with sensory loss |
Vasculitis
Hereditary neuropathy with predisposition to
pressure palsies
Infectious diseases (leprosy, Lyme, HIV)
Sarcoidosis
Compression and entrapment neuropathies |
Vasculitis is the most common diagnosis when
multiple nerves not normally subject to
compression are involved. Compressive
mononeuropathy, radiculopathy should be
considered with single nerve/region
involvement. |
|
Asymmetric distal weakness without sensory
loss |
Upper-motor-neuron disease
Generalized: multifocal motor neuropathy (MMP) |
Bulbar findings (i.e., slurred or nasal
speech, drooling, nasal regurgitation of
liquids, difficulty whistling, swallowing),
fasciculations,and hyperreflexia suggest
upper-motor-neuron disease, and are rare
with MMP |
|
Asymmetric proximal and distal weakness with
sensory loss |
Polyradiculopathy
Plexopathy (brachial or lumbar)
Meningeal carcinomatosis or lymphomatosis |
In diabetic plexopathy, pain typically
precedes weakness |
|
Symmetric sensory loss without weakness |
Cryptogenic sensory polyneuropathy (CSPN)
Metabolic derangements (diabetes, alcohol),
drugs, toxins |
CSPN is primarily observed in older adults.
Diabetic and alcoholic neuropathies may
present with few or no motor signs. |
|
Asymmetric proprioceptive sensory loss
without weakness |
Sensory neuropathy (ganglionopathy)
Paraneoplastic syndrome
Sjögrens syndrome
Idiopathic sensory neuropathy
Drug (e.g., cisplatin and its analogues) or
vitamin B6 toxicity
HIV sensory neuropathy |
Primarily affects large fibers. May warrant
a cancer workup. |
|
Autonomic symptoms |
Generalized - diseases affecting small
fibers: e.g., acute dysautonomia, familial/
primary amyloidosis, GBS, diabetes, Chagas
disease, porphyria, HIV-related autonomic
neuropathy, idiopathic pandysautonomia |
Typically associated with other types of
neuropathy. Conduct autonomic testing (e.g.,
Valsalva heart rate response to pressure
changes). May be an early or sole
presentation of alcoholic or diabetic
neuropathy. |
|
Based on Barohn [6], Kowalske [13]. |
|
Table 8.
Assessment of Muscle-Group Weakness
|
|
Symptoms |
Likely source of weakness |
Slurred/nasal speech
Drooling
Nasal regurgitation of liquids
Difficulty whistling, smiling
Difficulty swallowing, weight loss |
Bulbar muscles |
Diplopia
Ptosis |
Extraocular muscles |
Trouble reaching
Difficulty holding razor, comb, hair dryer
Difficulty placing things in high cabinets |
Proximal upper-extremity muscles |
Difficulty opening jars, doors, using keys,
silverware
Trouble buttoning clothing |
Distal upper-extremity muscles |
Trouble rising from chairs, sofas
Trouble getting out of car, bath, or off
toilet
Difficulty climbing stairs |
Proximal lower-extremity muscles |
Tripping
Sprained ankles |
Distal lower-extremity muscles |
|
Table 9. Principal
Motor Innervation of Peripheral Nerves:
Localizing Muscle Weakness
|
|
Nerves |
Muscles |
Action |
|
Axillary |
Deltoid |
Shoulder abduction |
|
Musculocutaneous |
Biceps, brachialis |
Flexion of elbow |
|
Median |
Flexor carpi radialis |
Radial flexion of wrist |
|
Flexor digitorum sublimis |
Flexion of middle phalanges (digiti II-V) |
|
Flexor digitorum profundus (lateral half) |
Flexion of distal phalanges (digiti II, III) |
|
Pronator teres, pronator quadratus |
Pronation of forearm |
|
Abductor pollicis brevis |
Abduction of thumb |
|
Opponens pollicis brevis |
Opposition of thumb |
|
Flexor pollicis longus |
Flexion of distal phalanx of thumb |
|
Flexor pollicis brevis |
Flexion of proximal phalanx of thumb |
|
Ulnar |
Flexor carpi ulnaris |
Ulnar flexion of wrist |
|
Flexor digitorum profundus (medial half) |
Flexion of distal phalanges (digiti IV, V) |
|
Abductor digiti minimi |
Abduction of digiti V |
|
All other intrinsics of hand |
Finger abduction/adduction |
|
Radial |
Triceps |
Extension at elbow |
|
Brachioradialis |
Flexion of forearm |
|
Extensor carpi radialis/ulnaris |
Extension at wrist with radial/ulnar
deviation |
|
Supinator |
Supination of forearm |
|
Extensor pollicis brevis |
Extension of thumb (proximal) |
|
Extensor pollicis longus |
Extension of thumb (distal) |
|
Extensor indicis proprius |
Extension of index (proximal) |
|
Extensor digiti V proprius |
Extension of little finger (proximal) |
|
Extensor digiti communis |
Extension of digits (II-V, proximal) |
|
Femoral |
Iliopsoas |
Flexion of thigh at hip |
|
Quadriceps |
Extension of leg at knee |
|
Obturator |
Adductor longus, adductor brevis, adductor
magnus |
Adduction of thigh at hip |
|
Superior gluteal |
Gluteus medius, gluteus minimus, gluteus
maximus |
Abduction of thigh at hip |
|
Sciatic |
Biceps femoris, semitendinosus,
semimembranosus |
Flexion of leg at knee |
|
Sciatic branches: fibular (deep) |
Tibialis anterior |
Dorsiflexion of foot |
|
Extensor digitorum longus |
Extension of toes |
|
Extensor hallucis longus |
Extension of great toe |
|
Sciatic branches: fibular (superficial) |
Peroneus |
Everts foot |
|
Tibial |
Gastrocnemius, soleus |
Plantar flexion of foot |
|
Flexor digitorum longus |
Flexion of distal phalanges (II-IV) |
|
Flexor hallucis longus |
Flexion of distal phalanges (I) |
|
Flexor digitorum brevis |
Flexion of middle phalanges (II-V) |
|
Flexor hallucis brevis |
Flexion of middle phalanges (I) |
|
Pudendal |
Perineal and sphincters |
Closure of sphincters, contraction of pelvic
floor |
|
From Ronthal [14]. |
|
Table 7. Key
Findings from History and Physical
Examination: Pattern Recognition for
Generalized Neuropathies
|
|
Pattern |
Classification/possible diagnoses |
Comments |
|
Symmetric proximal and distal weakness with
sensory loss |
Inflammatory demyelinating polyneuropathy
Guillain-Barré syndrome (GBS)
Chronic inflammatory demyelinating
polyneuropathy |
Patient complaints include: difficulty
raising arms to brush teeth and comb hair,
problems climbing stairs, difficulty rising
from a seated position, sensory loss, and
sensory ataxia |
|
Symmetric distal weakness with sensory loss |
Metabolic disorders (e.g., amyloidosis,
diabetes, Sjögrens syndrome)
Drugs (amitriptyline, chloroquine, dapsone)
and toxins
Hereditary neuropathies (Charcot-Marie-Tooth
disease, amyloidosis) |
Underlying conditions may be axonal or
demyelinating;
therefore, laboratory investigations (e.g.,
fasting blood sugar, hemoglobin
A1C, vitamin B12
levels, molecular genetic blood tests) are
recommended based on initial suspicions |
|
Asymmetric distal weakness with sensory loss |
Vasculitis
Hereditary neuropathy with predisposition to
pressure palsies
Infectious diseases (leprosy, Lyme, HIV)
Sarcoidosis
Compression and entrapment neuropathies |
Vasculitis is the most common diagnosis when
multiple nerves not normally subject to
compression are involved. Compressive
mononeuropathy, radiculopathy should be
considered with single nerve/region
involvement. |
|
Asymmetric distal weakness without sensory
loss |
Upper-motor-neuron disease
Generalized: multifocal motor neuropathy (MMP) |
Bulbar findings (i.e., slurred or nasal
speech, drooling, nasal regurgitation of
liquids, difficulty whistling, swallowing),
fasciculations,and hyperreflexia suggest
upper-motor-neuron disease, and are rare
with MMP |
|
Asymmetric proximal and distal weakness with
sensory loss |
Polyradiculopathy
Plexopathy (brachial or lumbar)
Meningeal carcinomatosis or lymphomatosis |
In diabetic plexopathy, pain typically
precedes weakness |
|
Symmetric sensory loss without weakness |
Cryptogenic sensory polyneuropathy (CSPN)
Metabolic derangements (diabetes, alcohol),
drugs, toxins |
CSPN is primarily observed in older adults.
Diabetic and alcoholic neuropathies may
present with few or no motor signs. |
|
Asymmetric proprioceptive sensory loss
without weakness |
Sensory neuropathy (ganglionopathy)
Paraneoplastic syndrome
Sjögrens syndrome
Idiopathic sensory neuropathy
Drug (e.g., cisplatin and its analogues) or
vitamin B6 toxicity
HIV sensory neuropathy |
Primarily affects large fibers. May warrant
a cancer workup. |
|
Autonomic symptoms |
Generalized - diseases affecting small
fibers: e.g., acute dysautonomia, familial/
primary amyloidosis, GBS, diabetes, Chagas
disease, porphyria, HIV-related autonomic
neuropathy, idiopathic pandysautonomia |
Typically associated with other types of
neuropathy. Conduct autonomic testing (e.g.,
Valsalva heart rate response to pressure
changes). May be an early or sole
presentation of alcoholic or diabetic
neuropathy. |
|
Based on Barohn [6], Kowalske [13]. |
|
Table 16.
Management of Neuropathic Pain
|
|
Symptom |
Treatment |
|
Mild neuropathic pain |
Simple non-narcotic analgesics such as
nonsteroidal anti-inflammatory agents or
tramadol hydrochloride up to 50 mg PO t.i.d.
may be helpful for all types of pain |
|
Diffuse, poorly localized pain |
Amitriptyline, 10-150 mg/day, in gradually
increasing dosages (contraindicated in heart
block, urinary tract obstruction, or
narrow-angle glaucoma)
If orthostatic hypotension is
problematic: Other tricyclic
depressants, including nortriptyline |
|
Sharp, well-localized pain |
Carbamazepine: initial dose, 100 mg b.i.d.;
gradually increasing to 400-1,200 mg/day as
tolerated
If carbamazepine is not tolerated:
Phenytoin, in gradually increasing doses
beginning with 300 mg/day
Gabapentin, beginning with 100-300 mg/day
and titrating up to 600 mg t.i.d. or more
Capsaicin, 0.075% topical ointment, applied
q.i.d.
For both diffuse and sharp pains:
Mexiletine, up to 10 mg/kg/day |
|
Lancinating pains |
Clonazepam, 0.5-10.0 mg/day |
|
Nocturnal leg pain, cramping |
Clonidine, 0.1-0.5 mg q.h.s., quinine
sulfate 200-400mg at bedtime |
|
b.i.d., twice daily; q.h.s., before bedtime;
q.i.d., 4 times a day; PO, orally; t.i.d., 3
times a day. |
|
Modified from Lynn and Mendell [11]. |
|
|
| Diagnosis |
 |
|